I'm going out on a limb & saying Crescent are offloading their shares?
I think the stock is selling at peak pessimism (limited downside). Yes, revenues will be hit by reduced covid testing, however people will be getting out more to see GP's etc so assume pathology testing will chug along at a slow 3-4% growth rate. If mgmt can control cost & run the business efficiently as they mention is their focus there is a nice upside on this from current valuation. IMO based on the information that is available, this is a $1B business.
Not advice!!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.83 |
Change
-0.040(1.39%) |
Mkt cap ! $555.7M | |||
| Open | High | Low | Value | Volume |
| $2.87 | $2.89 | $2.83 | $1.569M | 550.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 23208 | $2.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.85 | 11000 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| ACL (ASX) Chart |